LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 472

Search options

  1. Article ; Online: The European medical information framework: A novel ecosystem for sharing healthcare data across Europe.

    Lovestone, Simon

    Learning health systems

    2019  Volume 4, Issue 2, Page(s) e10214

    Abstract: Introduction: The European medical information framework (EMIF) was an Innovative Medicines Initiative project jointly supported by the European Union and the European Federation of Pharmaceutical Industries and Associations, that generated a common ... ...

    Abstract Introduction: The European medical information framework (EMIF) was an Innovative Medicines Initiative project jointly supported by the European Union and the European Federation of Pharmaceutical Industries and Associations, that generated a common technology and governance framework to identify, assess and (re)use healthcare data, to facilitate real-world data research. The objectives of EMIF included providing a unified platform to support a wide range of studies within two verification programmes-Alzheimer's disease (EMIF-AD), and metabolic consequences of obesity (EMIF-MET).
    Methods: The EMIF platform was built around two main data-types: electronic health record data and research cohort data, and the platform architecture composed of a set of tools designed to enable data discovery and characterisation. This included the EMIF catalogue, which allowed users to find relevant data sources, including the data-types collected. Data harmonisation via a common data model were central to the project especially for population data sources. EMIF also developed an ethical code of practice to ensure data protection, patient confidentiality and compliance with the European Data Protection Directive, and GDPR.
    Results: Currently 18 population-based disease agnostic and 60 cohort-based Alzheimer's data partners from across 14 countries are contained within the catalogue, and this will continue to expand. The work conducted in EMIF-AD and EMIF-MET includes standardizing cohorts, summarising baseline characteristics of patients, developing diagnostic algorithms, epidemiological studies, identifying and validating novel biomarkers and selecting potential patient samples for pharmacological intervention.
    Conclusions: EMIF was designed to provide a sustainable model as demonstrated by the sustainability plans for EMIF-AD. Although network-wide studies using EMIF were not conducted during this project to evaluate its sustainability, learning from EMIF will be used in the follow-on IMI-2 project, European Health Data and Evidence Network (EHDEN). Furthermore, EMIF has facilitated collaborations between partners and continues to promote a wider adoption of principles, technology and architecture through some of its continued work.
    Language English
    Publishing date 2019-12-25
    Publishing country United States
    Document type Journal Article
    ISSN 2379-6146
    ISSN (online) 2379-6146
    DOI 10.1002/lrh2.10214
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Fleshing out the amyloid cascade hypothesis: the molecular biology of Alzheimer's disease.

    Lovestone, S

    Dialogues in clinical neuroscience

    2011  Volume 2, Issue 2, Page(s) 101–110

    Abstract: Alzheimer's disease (AD) is a disorder of two pathologies- plaques and tangles. The former have as a key constituent amyloid protein and the latter the microtubule-associaied protein tau. Genetics has demonstrated that changes in either protein are ... ...

    Abstract Alzheimer's disease (AD) is a disorder of two pathologies- plaques and tangles. The former have as a key constituent amyloid protein and the latter the microtubule-associaied protein tau. Genetics has demonstrated that changes in either protein are sufficient to cause dementia. The amyloid cascade hypothesis proposes that plaque-related changes precede tangle-related changes and positions amyloid as central to the degeneration of AD. All the evidence suggests this is correct, including evidence that presenil ins alter the processing of the amyloid precursor protein and evidence that disrupting the normal properties of tau underlies the related froniotemporal dementias. The amyloid cascade hypothesis has provided the basis for nearly a decade of intensive basic science - the skeleton of that hypothesis can now be fleshed out, and confidence is growing that this will result in useful disease-modifying therapies in the future.
    Language English
    Publishing date 2011-10-27
    Publishing country France
    Document type Journal Article
    ZDB-ID 2188781-0
    ISSN 1294-8322
    ISSN 1294-8322
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Book: Early diagnosis and treatment of Alzheimer's disease

    Lovestone, Simon

    1998  

    Author's details Simon Lovestone
    Language English
    Size 80 S. : Ill., graph. Darst.
    Publisher Dunitz
    Publishing place London
    Publishing country Great Britain
    Document type Book
    HBZ-ID HT009518647
    ISBN 1-85317-580-3 ; 978-1-85317-580-0
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  4. Article ; Online: Insulin signalling in Alzheimer's disease and diabetes: from epidemiology to molecular links.

    Ribe, E M / Lovestone, S

    Journal of internal medicine

    2016  Volume 280, Issue 5, Page(s) 430–442

    Abstract: As populations across the world both age and become more obese, the numbers of individuals with Alzheimer's disease and diabetes are increasing; posing enormous challenges for society and consequently becoming priorities for governments and global ... ...

    Abstract As populations across the world both age and become more obese, the numbers of individuals with Alzheimer's disease and diabetes are increasing; posing enormous challenges for society and consequently becoming priorities for governments and global organizations. These issues, an ageing population at risk of neurodegenerative diseases such as Alzheimer's disease and an increasingly obese population at risk of metabolic alterations such as type 2 diabetes, are usually considered as independent conditions, but increasing evidence from both epidemiological and molecular studies link these disorders. The aim of this review was to highlight these multifactorial links. We will discuss the impact of direct links between insulin and IGF-1 signalling and the Alzheimer's disease-associated pathological events as well as the impact of other processes such as inflammation, oxidative stress and mitochondrial dysfunction either common to both conditions or perhaps responsible for a mechanistic link between metabolic and neurodegenerative disease. An understanding of such associations might be of importance not only in the understanding of disease mechanisms but also in the search for novel therapeutic options.
    MeSH term(s) Aging/metabolism ; Alzheimer Disease/complications ; Alzheimer Disease/metabolism ; Animals ; Brain/metabolism ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/metabolism ; Humans ; Inflammation/metabolism ; Insulin/metabolism ; Insulin-Like Growth Factor I/metabolism ; Mitochondria/metabolism ; Neurons/metabolism ; Oxidative Stress ; Signal Transduction
    Chemical Substances Insulin ; Insulin-Like Growth Factor I (67763-96-6)
    Language English
    Publishing date 2016-11
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 96274-0
    ISSN 1365-2796 ; 0954-6820
    ISSN (online) 1365-2796
    ISSN 0954-6820
    DOI 10.1111/joim.12534
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Blood biomarkers for Alzheimer's disease.

    Lovestone, Simon

    Genome medicine

    2014  Volume 6, Issue 8, Page(s) 65

    Abstract: Simon Lovestone discusses recent progress in the development of molecular biomarkers for the diagnosis and prognosis of Alzheimer's disease. ...

    Abstract Simon Lovestone discusses recent progress in the development of molecular biomarkers for the diagnosis and prognosis of Alzheimer's disease.
    Language English
    Publishing date 2014
    Publishing country England
    Document type Journal Article
    ZDB-ID 2484394-5
    ISSN 1756-994X
    ISSN 1756-994X
    DOI 10.1186/s13073-014-0065-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Will We Have a Drug for Alzheimer's Disease by 2030? The View From Pharma.

    Lovestone, Simon / Manji, Husseini K

    Clinical pharmacology and therapeutics

    2019  Volume 107, Issue 1, Page(s) 79–81

    MeSH term(s) Alzheimer Disease/drug therapy ; Alzheimer Disease/etiology ; Alzheimer Disease/pathology ; Drug Development ; Drug Industry ; Humans ; Immunologic Factors/pharmacology ; Neuroprotective Agents/pharmacology ; tau Proteins/metabolism
    Chemical Substances Immunologic Factors ; MAPT protein, human ; Neuroprotective Agents ; tau Proteins
    Language English
    Publishing date 2019-11-23
    Publishing country United States
    Document type Journal Article
    ZDB-ID 123793-7
    ISSN 1532-6535 ; 0009-9236
    ISSN (online) 1532-6535
    ISSN 0009-9236
    DOI 10.1002/cpt.1685
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Treatment with TNF-α inhibitors versus methotrexate and the association with dementia and Alzheimer's disease.

    Kern, David M / Lovestone, Simon / Cepeda, M Soledad

    Alzheimer's & dementia (New York, N. Y.)

    2021  Volume 7, Issue 1, Page(s) e12163

    Abstract: Introduction: Peripheral inhibition of tumor necrosis factor (TNF)-α, outside of the central nervous system, may result in clinical improvement of Alzheimer's disease (AD) outcomes. TNF-α inhibitors (TNFIs) are effective treatments for various ... ...

    Abstract Introduction: Peripheral inhibition of tumor necrosis factor (TNF)-α, outside of the central nervous system, may result in clinical improvement of Alzheimer's disease (AD) outcomes. TNF-α inhibitors (TNFIs) are effective treatments for various autoimmune conditions and may be effective for preventing and/or treating AD. The objective of this study was to compare the risk of dementia and AD in patients initiating methotrexate versus those initiating TNFIs.
    Methods: Insurance claims data from databases of commercially insured and Medicare-eligible patients were used to estimate the risk of dementia and AD within patients with rheumatoid arthritis (RA) initiating a TNFI versus initiation of methotrexate. A sensitivity analysis included all patients without the RA diagnosis requirement. The at-risk period spanned from the index date until a diagnosis of the outcome, loss-to-follow-up, or receipt of the comparator drug. Patients were matched 1-to-1 using propensity scores. A Cox proportional hazards model was used to estimate the hazard ratio (HR). Negative controls were used to calibrate the results.
    Results: A total of 11,092 new TNFI patients and 44,023 new methotrexate patients were identified, and 8925 from each group were matched. The outcome of dementia occurred in 1.4% of patients in both groups. The calibrated results from the Cox regression found no difference between the two groups (commercially insured database: calibrated HR = 0.69, 95% confidence interval = 0.45 to 1.05; Medicare-only database: 1.14, 0.66 to 1.96). Results were similar in all sensitivity analyses: outcome of AD and including patients without RA.
    Discussion: No significant difference for the risk of dementia or AD was seen between patients initiating a TNFI versus methotrexate. Although this study cannot conclude whether use of TNFIs is protective against dementia and AD compared with receiving no treatment, there was no evidence that it is more protective than the active comparator methotrexate.
    Language English
    Publishing date 2021-09-20
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2832891-7
    ISSN 2352-8737 ; 2352-8737
    ISSN (online) 2352-8737
    ISSN 2352-8737
    DOI 10.1002/trc2.12163
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Trait, state, and mechanism: looking back, looking forward, and understanding why.

    Lovestone, Simon

    Journal of Alzheimer's disease : JAD

    2013  Volume 33 Suppl 1, Page(s) S23–33

    Abstract: The papers selected by the Journal of Alzheimer's Disease for commentary cover three interlinked areas of research: the search for genetic susceptibility of trait markers, the search for biomarkers or state markers, and the search for novel therapeutic ... ...

    Abstract The papers selected by the Journal of Alzheimer's Disease for commentary cover three interlinked areas of research: the search for genetic susceptibility of trait markers, the search for biomarkers or state markers, and the search for novel therapeutic targets through an understanding of the mechanisms of disease. This work is reviewed and some directions of travel for the next phase of research suggested. Specifically both state and trait marker research will benefit from advances in technology but will require, on the one hand, larger sample sets and, on the other, the use of study designs other than case-control. Routine collection of data through the electronic medical record coupled with samples collected in clinical care represents a major opportunity to scale these studies. Success in identifying trait markers for stratification and state markers for experimental medicine may be necessary to exploit the increased understanding of mechanisms and the new therapeutic opportunities this is allowing.
    MeSH term(s) Alzheimer Disease/genetics ; Genetic Markers ; Genetic Predisposition to Disease ; Humans ; Research ; Research Design
    Chemical Substances Genetic Markers
    Language English
    Publishing date 2013
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 1440127-7
    ISSN 1875-8908 ; 1387-2877
    ISSN (online) 1875-8908
    ISSN 1387-2877
    DOI 10.3233/JAD-2012-129014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Biomarkers in Alzheimer's disease.

    Lovestone, S

    The journal of nutrition, health & aging

    2006  Volume 10, Issue 2, Page(s) 118–122

    MeSH term(s) Alzheimer Disease/diagnosis ; Alzheimer Disease/drug therapy ; Alzheimer Disease/pathology ; Biomarkers/analysis ; Biomarkers/blood ; Biomarkers/cerebrospinal fluid ; Clinical Trials as Topic ; Disease Progression ; Humans ; Severity of Illness Index
    Chemical Substances Biomarkers
    Language English
    Publishing date 2006-03
    Publishing country France
    Document type Journal Article
    ZDB-ID 2081921-3
    ISSN 1760-4788 ; 1279-7707
    ISSN (online) 1760-4788
    ISSN 1279-7707
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Book: Depression in elderly people

    Lovestone, Simon / Howard, Robert

    1996  

    Author's details Simon Lovestone ; Robert Howard
    Keywords Depression / in old age ; Depression / therapy
    Language English
    Size VIII, 71 S. : Ill., graph. Darst.
    Publisher Dunitz
    Publishing place London
    Publishing country Great Britain
    Document type Book
    Note Bibliography: p65-67. - Includes index
    HBZ-ID HT007464141
    ISBN 1-85317-245-6 ; 978-1-85317-245-8
    Database Catalogue ZB MED Medicine, Health

    Kategorien

To top